Introduction
The human orofacial region is incredibly important, as it not only serves as our gateway to the environment, but also permits ingestion, taste, communication and facial recognition. It is not surprising, then, that birth defects affecting the mouth and face are among the most devastating. Indeed, the most common of all birth defects are clefts in the lip and palate-occurring in approximately 1 in 1000 children annually (Research, 2011) . Despite this, the mechanisms that cause orofacial clefts are still not completely understood, likely due to their multifactorial nature and the difficulty of in vivo studies in mammalian models. We have turned to the frog, Xenopus, to gain better insight into the etiology of facial clefts. The conserved orofacial region is easily accessible through all stages of development, thereby offering an array of molecular and embryological approaches to study the complex developmental events of orofacial development.
The orofacial region develops from seven facial prominences: the singular frontonasal and paired lateral nasal, maxillary and mandibular prominences. These prominences grow and converge to surround the embryonic mouth (for reviews see Jugessur et al., 2009; Liu et al., 2010; Tapadia et al., 2005) . Fusion of the maxillary and nasal prominences with the frontonasal prominence dorsal to the mouth opening forms the upper lip and primary palate (Greene and Pisano, 2010; Jiang et al., 2006; Meng et al., 2009) . Later, bilateral outgrowths from the maxillary prominence fuse to form the secondary palate, a specialized characteristic of amniotes. The primary and secondary palates, as well as the upper lip, create an important separation between the oral opening and nasal passage. Much attention has been paid to the development of the secondary palate, since defects in its formation are attributed to many forms of cleft palate in humans. However, less is known about the development of the upper lip and primary palate despite the fact that defects in these structures also result in several forms of cleft lip and palate, and may be an underlying cause of many forms of secondary cleft palate (Greene and Pisano, 2010; Jiang et al., 2006; Meng et al., 2009) .
Proper development of the palate and upper lip requires interactions between neural crest, forebrain, ectoderm mesoderm and pharyngeal endoderm (Couly et al., 2002; Hu and Helms, 1999; Ruhin et al., 2003) . Precise cell growth, migration, fusion and apoptosis are also necessary for the formation of this region. Therefore, it follows that the development of the orofacial structure involves a complex network of transcription factors and signaling pathways (Brugmann et al., 2006; Greene and Pisano, 2010) . The critical signaling molecule, retinoic acid, has numerous endogenous roles in the development of this region and has long been associated with craniofacial defects (reviewed in Mark et al., 2004) . Retinaldehyde is oxidized into retinoic acid by retinol dehydrogenases (RALDH), thereby allowing it to diffuse into neighboring cells, bind to RXR and RAR nuclear receptors, and activate transcription (Duester, 2008) . Misregulation of retinoic acid signaling has been associated with orofacial clefts in mammals. For example, mice deficient in members of the RALDH or RAR gene families exhibit craniofacial defects, including cleft lip (Dupe and Pellerin, 2009; Halilagic et al., 2007) . Additionally, an excess of retinoic acid -such as Accutane exposure during pregnancy -has been correlated with cleft lip and palate in humans and animal models (Malvasi et al., 2009; Vieux-Rochas et al., 2007) . Together, these studies suggest that normal orofacial development requires precise regulation of the retinoic acid signaling gradient.
How misregulation of retinoic acid signaling results in orofacial clefts is not completely clear. Canonical retinoic acid signaling activates transcription, and it is therefore predicted to be necessary for activation of one or more genes that regulate orofacial morphogenesis. Some of the most well studied genes activated transcriptionally by retinoic acid signaling are those belonging to the Homeobox gene family (Glover et al., 2006) . Members of this family are transcription factors characterized by the presence of a well conserved DNA binding domain called the homeodomain. In addition to the homeodomain, some homeobox genes also have other domains (such as LIM, POU and paired domains) that provide an additional level of DNA binding specificity (Foronda et al., 2009) . While much is known about how retinoic acid regulates homeobox genes in the brain (Glover et al., 2006) , little is known about this interaction in the facial region. Several homeobox genes are expressed in the orofacial region including msx (muscle segment homeobox) and lhx (lim homeobox) gene family members (Alappat et al., 2003; Washbourne and Cox, 2006; Zhadanov et al., 1995; Zhang et al., 2002) . Further, misregulation of such homeobox genes has been shown to result in orofacial clefts in mice, and has been correlated with cases of cleft palate in humans (Satokata and Maas, 1994; Zhao et al., 1999 ).
In the current study, we show that retinoic acid does in fact regulate expression of the homeobox genes msx2 and lhx8 in the orofacial region. Misregulation of retinoic acid and loss of these homeobox genes both result in failure of the dorso-anterior facial prominences to undergo growth and convergence resulting in a specific type of cleft -a median facial cleft (Allam et al., 2011) . Further, the cartilage elements associated with the upper lip and primary palate are either missing or malformed. We show that this phenotype may in part be due to a disruption in cell proliferation and differentiation. These results suggest a novel role for retinoic acid in the regulation of craniofacial development in directing the development of the upper lip and primary palate.
Materials and methods

Embryos
Xenopus laevis embryos were obtained and cultured using standard methods (Sive et al., 2000) . Embryos were staged according to Nieuwkoop and Faber (Nieuwkoop and Faber, 1967) .
In situ hybridization
In situ hybridizations were performed on isolated heads as described (Sive et al., 2000) , omitting the proteinase K treatment. cDNAs used to transcribe in situ hybridization probes were RALDH2 (AF310252.1, from Openbiosystems, MXL1736-99822041), RARγ (BC071082.1, from Openbiosystems, MXL1736-9507435), AP-2 (Winning et al., 1991) , lhx8 (BC057730, from Openbiosystems, MXL1736-8950926), and msx2 (CA792675.1, from Openbiosystems, EXL1051-5637033).
Morpholinos and transplants
Antisense morpholinos were purchased from Genetools. RALDH2 morpholino was designed and validated by Strate et al. (2009) , msx2 splice blocking morpholino was designed and validated by Khadka et al. (2006) and a translation blocking lhx8 morpholino was designed by Genetools (sequence available upon request). A standard control morpholino was used as a control in all experiments. Transplants from morphants to uninjected siblings and vice versa were performed as described (Dickinson and Sive, 2009 ). Rescue of the RALDH2 morpholino was performed in a matched experiment where 10 embryos (st. 24) that were injected with fluorescently labeled RALDH2 morpholino were chosen with identical fluorescence (intensity and location) and phenotype. Half of these identical embryos were treated with 5 μM ATRA and half were treated with carrier (ethanol). The same procedure was performed with embryos injected with control morpholino. lhx8 ORF was cloned into pCS2+ plasmid and RNA in vitro transcribed using the mMessage Machine kit (Ambion) to use for lhx8 morpholino rescue experiments.
Chemical treatments
Stock solutions were RAR inhibitor (BMS-453, Tocris (3409), 10 mM in DMSO), RALDH2 inhibitor (citral, Fluka (27450)), wee-1 inhibitor (PD-407824 Sigma (PZ0111), 10 mM stock in DMSO), alltrans retinoic acid (Sigma (R2625), 10 mM stock in DMSO), hydroxyurea (sigma (H8627), 500 mM stock in water), and aphidicolin (sigma (A0781) 15 mM stock in DMSO). Embryos were bathed in inhibitor solutions combined with 1% DMSO in 0.1% MBS (modified Barth's saline, pH 7.8) in culture dishes.
Immunohistochemistry and phalloidin staining
Specimens were embedded in 4% low-melt agarose (SeaPlaque GTG, Cambrex) and sectioned with a 5000 Series Vibratome at 75-100 μm. Immunohistochemistry was performed as described (Dickinson and Sive, 2006 ) using a polyclonal anti-ph3 antibody (Millipore, 06-570, diluted 1:1000), rabbit anti-cleaved caspase-3 (Cell Signalling, 9661S, diluted 1:1000) or mouse anti-collagen II (DSHB, II-II6B3, diluted 1:100). Appropriate secondary AlexaFluor 488 antibodies (Invitrogen) were diluted 1:500. Counterstains included 0.1% propidium iodide (Sigma, P4864) or Phalloidin (Invitrogen, A12379).
Fate mapping
Fate mapping was performed as described previously (Dickinson and Sive, 2006) . Briefly a 25-50 nl drop of 1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanin (CM-DiI; 2 mg/ml, Molecular Probes) using an Eppendorf micro-pressure injector and a glass pulled capillary tube was placed just below the surface of the outer ectodermal cells. Embryos were fixed and labeled with phalloidin as described above.
Alcian blue staining
Cartilages were stained using standard protocols with some modifications (Taylor and Van Dyke, 1985) . Briefly, tadpoles were fixed in Bouin's fixative overnight at 4°C and then washed in 70% ethanol. They were then immersed in Alcian blue stain; (0.1 mg/ml Alcian blue in 1 part acetic acid:4 parts ethanol) for 3-4 days at RT. Embryos were washed in 1% HCL in 70% ethanol for 1-2 days and cleared in 2% potassium hydroxide and glycerol.
Microarray analysis and qRT-PCR
Tissue was collected from the orofacial region of the embryo at stage 30 (35 hpf) at the end of RAR inhibitor or control treatment. One hundred fifty dissections were performed for each treatment and stored in Trizol (Invitrogen) at −80°C. RNA preparation and microarray hybridization were performed as described previously (Dickinson and Sive, 2009) in collaboration with Dr. Myrna Serrano at the VCU NARF core facility. For RT-PCR, total RNA was isolated using Trizol extraction followed by a lithium chloride solution (Ambion) precipitation. cDNA was prepared using the Omniscript Kit (Qiagen) and standard PCR was performed using Apex Hotstart Mastermix. Primer sequences are available upon request.
Results
Early development of the upper lip and primary palate
The formation of the upper lip and primary palate has not yet been examined using modern techniques in the frog. Here, we present some of the first descriptions of orofacial morphogenesis in X. laevis.
At stages 32-35 (35 hpf) the bilaterally symmetrical first branchial or pharyngeal arch flanks each side of the stomodeum (Dickinson and Sive, 2006) (Fig. 1A,B) . Transverse sections through the orofacial region during this time indicate that the epithelial lined oral cavity, as identified by e-cadherin immunohistochemistry, is directly juxtaposed with the brain (Fig. 1B) . By stage 35, the facial prominences can subtly be distinguished from one another in whole embryo and in transverse sections. Dorsal to the stomodeum is the singular frontonasal prominence and the bilaterally symmetrical medial nasal prominences located just below the nasal placodes (Fig. 1C,D) . Lateral to the stomodeum, the first pharyngeal arch is subdivided into the dorsal maxillary and ventral mandibular prominences (Fig. 1C,D) . At stage 39, the stomodeum deepens (Fig. 1E ) and the mesenchyme of the maxillary and medial nasal prominences converges dorsally (Fig. 1F) . By stages 40 and 41 (66-76 hpf), the perforation of the mouth is complete and the foregut connects to the external environment (Fig. 1G,I ). Also at this time, mesenchymal cells move into the region separating the brain and the oral cavity (Fig. 1H,J) . As development proceeds, the tissue between the oral epithelium and brain thickens to eventually form the upper lip and primary palate.
Here, we have defined 40-66 hpf as the time when the region forming the upper lip and primary palate begins to morphologically develop. Our next goal was to determine how the initial development of this region is regulated, specifically by retinoic acid signaling.
RALDH2 and RARγ are expressed in complementary and overlapping regions of the maxillary and nasal prominences We first needed to determine which retinoic acid signaling components are expressed in the orofacial region in Xenopus just preceding the initial development of the upper lip and primary palate. We chose a specific developmental window, from stages 24 to 30 (26-35 hpf), when the craniofacial prominences are being specified and the neural crest has already migrated into the region. Two retinoic acid pathway members, RALDH2 and retinoic acid receptor gamma (RARγ), were uncovered in a microarray expression screen for genes enriched in the embryonic mouth and surrounding tissue (Dickinson and Sive, 2009 and unpublished) . Xenbase expression database and published reports support this data (Bowes et al., 2011; Lynch et al., 2011) . Expression of other RALDH genes (RALDH1 and RALDH3) is confined to the eye at the stages we were interested in (Lynch et al., 2011) . Further, other retinoic acid receptors (RARβ and RARα) are not expressed in the orofacial region during the specified time frame (Escriva et al., 2006; Shiotsugu et al., 2004) . Therefore, we focused on RARγ and RALDH2 expressions as likely effectors of retinoic acid signaling in the upper lip and primary palate.
In situ hybridizations indicate that RALDH2 expression during stages 24-30 is localized in the embryonic mouth anlage and a region corresponding to the medial and lateral nasal prominences bordering the frontonasal prominence (see representative stages 24 and 28, Fig. 2A ,C). RARγ is expressed in the future facial tissue corresponding to the first pharyngeal arch, as well as the medial nasal prominences at stage 24. Later at stage 28, it becomes refined in the paired maxillary and medial nasal prominences (Fig. 2C,B ). This RARγ expression domain directly borders and overlaps with the RALDH2 expression domain. To determine if RARγ was expressed in neural crest cells, we performed side by side in situ hybridizations with the neural crest marker, AP-2, and found that the RARγ expression pattern partly overlaps with this gene (Fig. 2E,F) . This result suggests the possibility that RARγ is expressed in neural crest cells, as well as the adjacent mesoderm.
We next asked whether the RARγ expressing tissue in the maxillary and medial nasal prominences contributes to the upper lip and primary palate area. The lipophilic dye, DiI, was injected dorsolaterally to the stomodeum (Fig. 2G ) corresponding to the RARγ expression domain at stages 28-30. Later, at stages 41-42, embryos were sectioned and counter labeled with phalloidin to provide context. The tissue located at the midline overlying the oral ectoderm was labeled with DiI in 90% of the embryos ( Fig. 2H ; n = 10). These results suggest that the RARγ expression region does indeed contribute to the upper lip and primary palate region dorsal to the mouth. The arrow points to the stomodeum (outlined in yellow dots) or embryonic mouth (outlined in red dots). B, D, F, H, J) Transverse sections through the facial prominences. E-cadherin labels epithelium (red), and all tissue is counterstained with phalloidin (which labels F-actin, green). Abbreviations: BA1; 1st branchial arch, cg; cement gland, mx; maxillary prominence, mnp; medial nasal prominence, ma; mandibular prominence, np; nasal placode or pit.
The data presented in this section prompted the hypothesis that retinoic acid signals emanate from the mouth anlage and nasal prominences, and are received by RARγ receptors in neural crest and/or mesenchymal cells in the developing maxillary and medial nasal prominences (see model Fig. 9 ). Such expression patterns and fate mapping results suggest that retinoic acid signaling may be integral to the formation of the primary palate and associated facial elements. Therefore, we tested this hypothesis using loss of function approaches.
Decreased RALDH2 results in an abnormal shape of the developing mouth, resembling a median orofacial cleft
We performed loss of function of the RA synthesizing enzyme, RALDH2, using translation blocking Morpholino stabilized antisense oligos (Morpholino (MO), Genetools) injected into one-cell stage embryos ( Fig. 3A) (Strate et al., 2009) . A standard control morpholino (CMO) from Genetools was used as a control. RALDH2 morphant embryos had various defects such as a narrower face, abnormal eyes and hyper-pigmentation (Fig. 3B,C) . Importantly, abnormal triangular shapes of the embryonic mouth were noted, including a dorsal median cleft, in approximately 40% of the RALDH2 morphants when compared to CMO injected (n = 90 in 3 experiments; Fig. 3B ,C). Rescue experiments with all-trans retinoic acid (ATRA) were performed to determine if the effect of RALDH2 MOs was specific. We found that 70% of the RALDH2 morphants had less severe facial defects, and no clefts, when treated with 5 μM ATRA (n = 10, in 2 experiments, Supplemental Fig. 1IA-D) . It should be noted that a full rescue of all facial phenotypes would not be expected since ATRA exposure was only during the time when we believed that decreased RALDH2 affects upper lip and primary palate development.
We next examined the orofacial phenotype in the transverse section and found that the oral cavity epithelium, labeled by e-cadherin, lined the cleft while mesenchymal cells were reduced dorsal to the cleft compared to the control. This suggests that the facial prominence mesenchyme did not converge or grow to populate the region dorsal to the mouth (Fig. 3D,E) .
While the above experiments were suggestive that RALDH2 is important for orofacial formation, it is also possible that the defects were secondary to abnormalities caused either at an earlier time or to a surrounding tissue. To further confirm that RALDH2 was acting specifically in the orofacial tissue at the time of palate and upper lip development, face transplants were performed to specifically localize the morpholinos as described previously (Dickinson and Sive, 2009 ). The early mouth anlage and surrounding 1st branchial arch from a morphant embryo (injected with fluorescently labeled RALDH2 or control morpholinos) were transplanted to the same location in an un-injected sibling embryo at 24 hpf (Fig. 3F) . The entire dorsal extent of RALDH2 and RARγ expressing tissue could not be transplanted since it caused defects to the developing brain in the control embryos (not shown). Therefore, these experiments represent only partial loss of function. Despite this, face transplanted RALDH2 morphants had an abnormally shaped mouth with an upward indent or cleft in 80% of the embryos compared to controls (n = 10, 2 replicates, Fig. 3G,H) . These results suggest that the oral clefts created when there is decreased RALDH2 in whole embryos is not simply due to earlier defects or abnormalities in surrounding tissue. The converse experiment was also performed, in which the face from an un-injected embryo was transplanted to the same location in a RALDH2 morphant (Fig. 3I) . In this case, the mouth shape was improved, having no cleft in 70% of morphants compared to unoperated RALDH2 morphants (n = 10, 2 replicates; Fig. 3J,K) . Control operated embryos were all normal. These results further confirm that RALDH2 is required specifically in the orofacial region, and that loss of this protein results in a dorsal oral cleft-like defect.
Another method to inhibit RALDH2 function is to apply the chemical, citral, to embryos Schuh et al., 1993) . When embryos were exposed to 100 μM citral (concentration comparable to previous studies ) from stages 24-30 (26-35 hpf) , an orofacial cleft was apparent in 83% of the embryos when compared to the controls (n = 12, 2 replicates; Supplemental Fig. 1IIII,J) .
Decreased RAR function also results in a median orofacial cleft
Since we found RARγ to be expressed in a complementary and overlapping pattern with RALDH2 in the orofacial region, we hypothesized that RARγ is a major receptor for retinoic acid in the orofacial region. Therefore, we used a well characterized RAR pharmacological inhibitor (BMS-453) Chen et al., 2004; Huang et al., 2011) . This inhibitor principally targets RARγ, and to a lesser extent RAR α and β. Since the latter two are not expressed in the orofacial region during the time frame examined, this inhibitor is assumed to primarily target RARγ in our studies.
Tadpoles at stages 24 to 30 (26-35 hpf) were treated with BMS-453 when RARγ is expressed in the facial prominences during early orofacial development (Fig. 4A) . At concentrations ranging from 0.5 μM to 10 μM an obvious median cleft was observed in 100% of the treated tadpoles (10 μM shown, Fig. 4B,C) . This defect was highlighted when the region was sectioned transversely and labeled for e-cadherin (an epithelial marker). The cleft was lined with epithelium and the palatal region dorsal to the oral cavity was deficient in mesenchymal cells when compared to controls (Fig. 4D,E) . All-trans retinoic acid (ATRA; 5 μM) applied at the same time as 0.5 μM of BMS-453 partially reduced the BMS-453 induced phenotype, and the cleft was no longer evident (Supplemental Fig. 1IIE-H) . These results are consistent with ATRA rescue of BMS-453 induced abnormalities in other organs Chen et al., 2004) . One possible reason for the orofacial malformations observed in tadpoles treated with the RAR inhibitor is that neural crest specification or migration is perturbed. However, the treatment time partially eliminates this possibility since we exposed embryos to the inhibitor after the neural crest initiates migration into the cranial region. Further, we examined a neural crest marker, AP-2 (de Croze et al., 2011) at the end of treatment and observed no obvious difference in expression patterns in BMS-453 treated tadpoles compared to the control group (Fig. 4F-I) . These results are consistent with experiments in mice where ablation of RARγ/β in the cranial neural crest cell lineage did not affect neural crest migration and specification (Dupe and Pellerin, 2009) . Significantly, such mutant mice were also reported to have a dorsal median cleft that closely resembles the cleft we observe in Xenopus.
We also asked whether RAR inhibitor treatment directly affected apoptosis or cell division. We examined a mitotic marker (phosphohistone H3; pH3) and apoptotic marker (cleaved caspase-3) at the end of the treatment. No obvious differences were noted in the number of mitotic and apoptotic cells in the maxillary, nasal and frontonasal prominences (Supplemental Fig. 2A-I) . These results suggest that BMS-453 is not directly affecting cell proliferation or apoptosis at the time of treatment, and is thus unlikely to be toxic. Additionally, the brain and nasal placodes have been shown to be major signaling centers for the development of the orofacial region . Therefore, defects in either of these structures may secondarily affect development of the upper lip and primary palate. However, upon examination of the neural structures after BMS-453 treatment, we did not see gross morphological defects in the brain and nasal pit using tubulin as a marker (Supplemental Fig. 3A-B) .
Loss of RAR function results in decreased transcriptional levels of the homeobox genes lhx8 and msx2
To uncover the mechanism by which retinoic acid signaling results in facial clefting, we examined changes in transcriptional levels of genes after loss of RARγ function. Briefly, embryos were treated with 10 μM BMS-453 as described above. At the end of the treatment the orofacial region was dissected, RNA extracted and microarray expression profile performed (data not shown). Our preliminary results revealed that the transcriptional levels of two homeobox genes, msx2 and lhx8, were downregulated by RAR inhibitor treatment. We first characterized the expression of these genes by in situ hybridization in normal developing embryos at a time when the RAR inhibitor was applied at stages 28-30 (32-35 h). We observed that lhx8 was expressed in bilaterally paired regions in the dorsal portion of the first branchial arch; a region that corresponds to the maxillary and medial nasal prominences (Fig. 5A) . Additionally, lhx8 was expressed in paired regions of the ventral/anterior base of the telencephalon. At the same stage, msx2 was expressed in a similar but smaller region in the maxillary and/or medial nasal prominences compared to lhx8 (Fig. 5B) . msx2 was also expressed in a ventral and slightly more posterior region at the base of the cement gland corresponding to a bmp4 expressing domain in the mandibular prominences (Bowes et al., 2011) . At stages 35-37 (50 hpf), lhx8 expression was similar to the earlier time (Fig. 5C ) while msx2 expression seemed to increase in area in the maxillary and/or medial nasal prominences (Fig. 5D) . In summary, both lhx8 and msx2 share overlapping expression with RARγ in the maxillary and nasal prominences (see Fig. 9A ) suggesting the possibility that these genes are indeed regulated by retinoic acid signaling. We tested this hypothesis further by examining lhx8 and msx2 expressions after RAR inhibitor treatment. In-situ hybridization of the two genes revealed a more diffuse expression pattern in the region of the maxillary and nasal prominences (Fig. 5C-F) . RT-PCR revealed that both lhx8 and msx2 appeared downregulated in treated embryos confirming the preliminary microarray results (Fig. 5G,H) . Taken together these experiments confirmed our hypothesis that retinoic acid signaling regulates lhx8 and msx2 expressions.
Combined loss of Msx2 and Lhx8 function results in a facial cleft mimicking inhibition of retinoic acid signaling
If retinoic acid signaling regulates Lhx8 and Msx2 then we would expect that loss of function of these homeobox genes would mimic decreased RALDH2 or RARγ. Downregulation of Lhx8 using 90 ng of a translation blocking MO resulted in a narrower face and close set eyes. Further, 15% of these lhx8 morphants had a subtle dorsal median cleft in the oral cavity (Supplemental Fig. 4A,B ; n = 71, 2 experiments). Since this was the first time this lhx8 MO has been tested we performed a rescue experiment to ensure its specificity. Low Fig. 5 . A-F) Frontal views of whole mount in situ hybridizations for lhx8 and msx2, (mRNA in blue). The arrow points to the stomodeum. G) Schematic showing the experimental plan H. H) RT-PCR using lhx8, msx2 and actin specific primers for control and RAR inhibitor treated tadpoles. Abbreviations: cg; cement. levels of lhx8 RNA (200 pg) that was not targeted by the MO was coinjected with 90 ng of lhx8 MO. We found that lhx8 RNA resulted in a 62% complete rescue and 38% partial rescue of the lhx8 morphant phenotype, where even the partially rescued tadpoles did not have an orofacial cleft (n = 84 in 2 experiments, Supplemental Fig. 4G-J) . Using up to 90 g of a validated msx2 splice blocking MO (Khadka et al., 2006) did not result in a median cleft. In fact only 20% of these msx2 morphants had a slightly malformed mouth opening (Supplemental Fig. 4C ; n = 91, 2 experiments). Double lhx8/msx2 morphants had a more profound phenotype with 63% of embryos exhibiting dorsal median clefts at lower concentrations than either lhx8 or msx2 morpholino alone (34 ng of each Lhx8MO and Msx2MO; n = 121, 2 experiments; Supplemental Fig. 4A-D) . In transverse sections of the lhx8/msx2 double morphants we observed that the clefts were an extension of the oral epithelium, and there were decreased mesenchymal tissues between the oral cavity and brain ( Fig. 6D-E) . These clefts did indeed appear similar to those observed in RALDH2 morphants and RAR inhibitor (BMS-453) treated embryos as predicted (compare Figs. 3C,E, 4C ,E to 6C,E). To further test that Lhx8 and Msx2 are regulated by retinoic acid signaling, we examined whether double lhx8/msx2 morphant phenotypes were significantly enhanced by the additional treatment of the RAR inhibitor. Embryos were injected with low levels of lhx8/msx2 MOs (17 ng of each) and then treated with low levels of BMS-453 (0.1 μM) at stage 24 (26 hpf). In either treatment alone a phenotype was not detected or very mild (n = 20/treatment in 2 experiments). However, when the lhx8/msx2 double morphants were also treated with the RAR inhibitor; 60% of the resulting embryos had a dorsal median cleft (Fig. 6F-J, n = 20, 2 experiments) . These results suggest a synergistic effect between the RAR inhibitor and lhx8/msx2 morpholinos. Therefore RAR, Lhx8 and Msx2 may exist within the same functional pathway.
Decreased retinoic acid signaling and Msx2/Lhx8 function results in fewer proliferating cells in the developing maxillary, nasal and frontonasal prominences While we observed that there was no obvious change in cell division or apoptosis directly after RAR inhibitor treatment, we noticed that later in development the face became narrower (see Figs. 3B,C and 4B,C). Loss of Msx2 and Lhx8 function also resulted in a similar phenotype (see Fig. 6B,C) . One possibility to explain this narrowing face phenotype is that there is decreased growth of the orofacial tissue due to later defects in cell division and/or cell survival. We examined markers for cell division (phospho-histone H3) and apoptosis (cleaved caspase-3) at stages 37-40 when face narrowing could first be detected after RAR inhibitor treatment. Results indicated that treated embryos had 56% less mitotic cells in the region of the maxillary and frontonasal prominences compared to the controls ( Fig. 7A,B ; Student t-test, p = 0.00013, compare outside the dotted regions). A more severe effect on cell division was observed in lhx8/msx2 double morphants (Fig. 7C,D) . However, no obvious change in cleaved caspase-3 immunohistochemistry was observed in the facial prominences of either RAR inhibitor treated or lhx8/ msx2 double morphants, suggesting that cell death did not increase (Supplemental Fig. 5A,B) . Thus, a possible mechanism to explain the narrow face and median cleft phenotype is that retinoic acid signaling via Lhx8 and Msx2 is required for tissue growth of the dorsal facial prominences.
To determine if cell cycle regulation was the primary reason for facial clefting we attempted to decrease cell division rates at stages when we observed facial thinning after RAR inhibitor treatments. We used a published method of inhibition of cell cycle in Xenopus, using a combination of hydroxyurea and aphidicolin (HU/A) in a bath application. Embryos were treated with HU/A at three different concentrations (150 μM/20 μM, 300 μM/20 μm and 75 μM/10 μM) at two different time periods (stages 26 to 31 or 32 to 41). While all treated embryos had malformed faces, we did not observe dorsal median clefts with any treatment (Supplemental Fig. 6 , n = 10 per treatment, 2 replicates for each treatment). These results suggest that decreased proliferation alone does not induce dorsal facial clefts, and does not account for the entire RAR inhibitor and lhx8/msx2 morphant phenotype. However, it is possible that decreased proliferation contributes to the cleft phenotype. Therefore, it might be expected that inhibition of a cell cycle checkpoint regulator could partially attenuate the phenotype resulting from RAR inhibition. Therefore, we examined the effect of a cell cycle checkpoint inhibitor, wee-1, (Palmer et al., 2006) on the phenotype created by the RAR inhibitor (Fig. 7E) . We observed that together, 10 μM of the wee-1 inhibitor and 1 μM of the RAR inhibitor resulted in embryos with a severely malformed face. However, the median cleft in these combined wee-1 and RAR inhibitor treated tadpoles appeared to be less sharp than that of the RAR inhibitor alone ( Fig. 7F-I ; 70%, n = 10, 2 experiments). These results suggest that decreased cell cycle may contribute partially to the median cleft phenotype observed after decreased RAR and Lhx8/Msx2 function.
Decreased retinoic acid signaling and Msx2/Lhx8 function results in defects in the formation of the dorso-anterior cartilage Since we observed that RALDH2 and msx2/lhx8 morphants, as well as tadpoles treated with the RAR inhibitor, had narrower faces and decreased cell proliferation in the dorsal facial prominences; we asked whether this resulted in later defects in the facial jaw cartilage. We examined cartilage by performing Alcian blue staining. RAR inhibitor treated embryos were missing dorso-anterior cartilages that contribute to the palate and upper lip. Specifically, the ethmoid plate, palatoquadrate, suprarostral and trabeculum cartilages were smaller or absent (Fig. 8A-D) . The cartilages were more severely affected in msx2/lhx8 double morphants, likely owing to the loss of these genes at earlier stages and their possible additional roles in early neural crest development (Khadka et al., 2006) . The cartilages also most deformed were the anterior-dorsal cartilages, many of which could not be identified (Fig. 8E-H) .
We next asked whether the cartilage forming chondrocytes differentiated in the primary palate region using collagen II protein as a marker. We did not observe collagen II protein in the dorso-anterior region in the RAR inhibitor treated embryos or lhx8/msx2 double morphants as it was in the controls (Fig. 8I-L) . These results suggest that the cells forming cartilage do not form in the region fated to become the upper lip and primary palate when embryos are depleted of retinoic acid signaling or Lhx8/Msx2 function. It is possible that not enough cells are generated, or that retinoic acid via Lhx8/Msx2 is also required for differentiation of the chondrocytes.
Discussion
Craniofacial development requires complex interactions between the epithelium, endoderm, mesoderm and cranial neural crest. Retinoic acid has been shown to affect such interactions at a number of different times and locations during the development of the pharyngeal arches and facial prominences (Abe et al., 2008; Bothe et al., 2011; Brickell and Thorogood, 1997; Kopinke et al., 2006; Mark et al., 2004; Mendelsohn et al., 1994; Niederreither et al., 2003) . In the present study, we show that retinoic acid is required for yet another aspect of orofacial development: formation of the upper lip and primary palate in X. laevis. Based on the results presented we propose a model whereby retinoic acid regulates expression of homeobox genes msx2 and lhx8, which in turn are responsible for tissue growth and differentiation of the facial prominences required for upper lip and primary palate development.
Median clefting and facial hypoplasia in vertebrates
Median facial hypoplasia, or median cleft lip and primary palate, are often attributed to deficiency or agenesis in midface development (Allam et al., 2011) . The phenotype ranges from severe defects in all median structures including the forebrain and nasal structures, to less severe defects such as a median cleft in the upper lip and primary palate. Such anomalies are seen in multiple craniofacial affected disorders such as Binder, Antley-Bixler, Crouzon, and fetal alcohol syndromes (Adolphs et al., 2011; Defraia et al., 2011; Johnson et al., 1996; Snyder-Warwick et al., 2010) . Clefts in the upper lip and primary palate have also been proposed to be an underlying cause of the more common clefts of the secondary palate (Jiang et al., 2006) .
While little is known about the genetic or environmental causes of median facial clefts, human cases of median orofacial clefts have been associated with retinoic acid and vitamin D deficiencies, as well as genetic mutations in Fgf receptors, Alx gene family members and the Six2 transcription factor (Beverdam et al., 2001; Fogelgren et al., 2008; Snyder-Warwick et al., 2010; Twigg et al., 2009) . A literature review also uncovered other affected genes in vertebrates displaying median clefts such as PDGF, kif3a, gli3, lhx8 and msx2 (Brugmann et al., 2010; Eberhart et al., 2008; Winograd et al., 1997; Zaghloul and Brugmann, 2011; Zhao et al., 1999) . Genetically or mechanistically, it has been unclear whether there are any connections between these genes during upper lip and palate development. Therefore, our goal was to begin to make inroads into further understanding the molecular mechanisms that underlie the development of the upper lip and primary palate. We initially focused on the role of retinoic acid as a possible major regulator of the dorsal orofacial region.
Retinoic acid signaling is required for upper lip and primary palate formation
Retinoic acid is well known for its role in craniofacial development, however little attention has been paid to its possible role in the formation of the upper lip and primary palate. In this study, we show that loss of retinoic acid signaling results in a median facial cleft in X. laevis. We also found that such median clefts are accompanied by defects in dorso-anterior cartilaginous structures. Specifically, we noted a loss of the ethmoid (which supports the base of the nasal cavity), the suprarostral plate (which supports the upper lip) and the palatoquadrate (which forms the posterior roof of the oral cavity). Similarly, a median cleft was also reported in RARα/RARγ mutant mice (Dupe and Pellerin, 2009; Lohnes et al., 1994) and mice deficient for endogenous retinoic acid synthesis (P. Dollé, unpublished observations). Associated skeletal defects in the RARα/ RARγ mutants also included dorso-anterior cartilages and bones such as the frontal and nasal bones, the medial rostral cranial base and the ethmoid cartilage . Together, these results suggest that the role for retinoic acid signaling in forming the upper lip and primary palate is conserved across vertebrates.
When retinoic acid signaling is disrupted, the palate and upper lip associated structures affected are the neural crest derivatives. Therefore, it might be reasonable, then, to speculate that retinoic acid deficiency affects the specification and/or migration of the neural crest. However, we and others have uncovered that retinoidinduced defects occur without any obvious alteration of the neural crest specification, migration or apoptosis (Gitton et al., 2010; Lohnes et al., 1994) . Further, it might also be postulated that median orofacial clefts are simply a side effect of defects in the formation of the brain and nasal placodes, which serve as major signaling centers for the face. However, we did not note any major abnormalities in the early formation of the brain or nasal pits in tadpoles treated with the retinoic acid inhibitor. Similarly, RARα/RARγ mutant mice had no defects in early brain development . Thus, retinoic acid signaling more likely targets receptors in neural crest and/or mesoderm cells at the time of facial prominence development and differentiation.
Retinoic acid signaling regulates expression of homeobox genes msx2 and lhx8
It has been well established that retinoic acid signaling regulates hox gene expression in the brain (reviewed in Glover et al., 2006) . Therefore, it was reasonable to speculate that retinoic acid may regulate similar homeodomain containing genes in the facial region. We found that retinoic acid indeed regulates two homeobox genes, msx2 and lhx8. Both genes have been shown to have important roles in craniofacial development, and loss of function of these genes also results in median clefts in mice (Alappat et al., 2003; Winograd et al., 1997; Zhao et al., 1999) . After RAR inhibitor treatment we observed decreased expression and a diffuse pattern of both msx2 and lhx8 in the orofacial region. Further, a synergistic effect was observed in tadpoles where RAR was inhibited and Msx2/Lhx8 were decreased, suggesting that these genes act in the same functional pathway. In support of these findings, it has also been reported that msx2 expression in the facial prominences is altered in response to changes in retinoic acid signaling in both mice and chick (Brown et al., 1997; Song et al., 2004; Washbourne and Cox, 2006) . We are the first to also report a connection between retinoic signaling and lhx8 expression.
It is possible that retinoic acid signaling regulates msx2 and lhx8 expressions directly. In support of this hypothesis, retinoic acid response elements (RARE domains) have been reportedly located 3′ and/or 5′ to the coding region of msx2 (reviewed in Alappat et al., 2003; Glover et al., 2006) . Further, examination of a 10 kB upstream region of both genes in Xenopus tropicalis indicates several RAR consensus binding sites (Transcription Element Search System, TESS) also suggesting possible direct regulation by retinoic acid signaling. Future ChiP studies await effective Xenopus RAR antibodies to determine if retinoic acid regulates msx2 and lhx8 directly in the formation of the upper lip and palate.
An alternative to direct activation is that retinoic acid signaling regulates Lhx8 and Msx2 indirectly by activating intermediate pathways. Such intermediate pathways may be bone morphogenetic protein (BMP) and fibroblast growth factor (FGF). Retinoic acid signaling has been implicated in regulating both of these signaling pathways during craniofacial development (Abe et al., 2008; Song et al., 2004) . Further, BMP has in turn been shown to control Msx gene family expression in mice and chick (reviewed in Greene and Pisano, 2010; Jugessur et al., 2009 ). There is also evidence that Fgf Abbreviations, sr; suprarostral, qua; quadrate, ir; infrarostral, Mk; Meckel's, ch; ceratohyal, bh; basihyal, eth; ethmoid, trab; trabecular, pq; palatoquadrate, np; nasal pit, oc; oral cavity. signaling can regulate Lhx8 during chick palate development (Inoue et al., 2006) . Such integration of signaling pathways would explain why perturbing BMP, FGF and retinoic acid can have similar effects on facial development.
Retinoic acid signaling and Msx2/Lhx8 function to regulate cell proliferation and differentiation in the dorso-anterior facial prominences
In our studies, RAR inhibition produced embryos with a median facial cleft associated with a narrower face and decreased cell proliferation. Additionally, msx2/lhx8 double morphants also displayed a median cleft associated with severe facial hypoplasia and decreased cell division. These results lead us to formulate the hypothesis that retinoic acid signaling via Lhx8 and Msx2 regulates proliferation in the orofacial region. Indeed, we did find a significant decrease in mitotic cells in lhx8/msx2 morphants and embryos treated with the RAR inhibitor, suggesting that this was a factor in the median clefting phenotype. Additionally, we could partially rescue the clefting phenotype induced by RAR inhibition with a cell cycle checkpoint inhibitor. However, we did not find that inhibition of cell cycle alone could illicit a facial cleft, suggesting that retinoic acid signaling may be responsible for other mechanisms such as differentiation and cell movements required for upper lip and palate development.
A role for retinoic acid, Lhx8 and Msx2 in regulating cell cycle is a plausible hypothesis based on a previous work. In fact, it has been suggested that a common mechanism of many teratogens that result in facial clefts, including retinoic acid, could be disruption of the cell cycle (Dhulipala et al., 2006) . Further, many homeobox proteins target cell cycle genes regulating tissue growth of various organs (Del Bene and Wittbrodt, 2005) . Msx and Lhx gene families, specifically, have been shown to regulate cell cycle during development. For example, one function of Msx2 is to maintain the facial mesenchyme in a proliferative undifferentiated state (Ishii et al., 2003) . Dodig et al. (1999) also showed that overexpression of Msx2 increases cell division in the palate, while loss of function has the opposite effect. Msx1 and 2 have also been reported to regulate cyclin D expression and thus control cell cycle progression directly (Hu et al., 2001) . While Lhx genes have been more widely shown to regulate cell fate, (reviewed in Zheng and Zhao, 2007) some Lhx family members have also been shown to regulate cell proliferation. For example, Lhx2 regulates neural precursor proliferation in the forebrain (Porter et al., 1997) . On the other hand, it is also possible that Lhx8 and/or Msx2 modulate differentiation of chondrocytes that form cartilage elements of the upper lip and primary palate development. Lhx gene family members have been shown to be part of the transcriptional networks which regulate odontogenic fates in mammalian dentition (Denaxa et al., 2009) , as well as pituitary specific cell fates (Colvin et al., 2009; Mullen et al., 2007) . The idea that Lhx8 and/or Msx2 may also regulate differentiation would explain why perturbing cell cycle alone does not fully mimic the loss of Lhx8 and Msx2 or retinoic acid signaling. This would also explain the lack of collagen II protein (a marker for differentiating chondrocytes) that forms in the primary palate region. Thus, our results suggest a possible dual role for Lhx8 and Msx2 in regulating both proliferation and differentiation and these two processes together are necessary for the development of the upper lip and primary palate.
Summary and conclusions
Our data brings together a model to explain the mechanism by which median facial clefts form in vertebrates. We propose that retinoic acid synthesized in the cells of the nasal prominences and stomodeum diffuses and binds to RARγ receptors in the mesenchymal cells of the maxillary and median nasal prominences (Fig. 9A ). RARγ either directly or indirectly activates transcription of the homeobox genes lhx8 and msx2. These genes in turn regulate proliferation and differentiation necessary for the growth and convergence of the facial prominences during palate and upper lip development (Fig. 9B,C) . Loss of retinoic acid, or both lhx8 and msx2, results in deficient tissue growth and differentiation so that the convergence and later fusion of the maxillary and nasal prominences with the frontonasal prominence does not occur. This leaves a large median gap in the upper lip and primary palate.
In conclusion, the complexity of palate morphogenesis is matched by an equally complex network of signaling molecules that include BMP, FGF, Wnt and SHH (Brugmann et al., 2006; Brugmann et al., 2007; Greene and Pisano, 2010; Jiang et al., 2006; Liu et al., 2010; Tapadia et al., 2005) . We have found that retinoic acid is also a critical player in this network of upper lip and primary palate regulators. We are currently performing a more extensive gene expression analysis to better understand how retinoic acid signaling interfaces with these other signaling pathways. Our work has the potential to better understand the complex nature of orofacial development which will lead to important insights into the etiology of human orofacial clefts.
Supplementary materials related to this article can be found online at doi:10.1016/j.ydbio.2012.02.033. showing expression domains of RALDH2, RARγ, lhx8 and msx2 overlaid onto the prospective facial prominences. B) A simple model of how retinoic acid and lhx8/msx2 regulate growth and differentiation of the prominences that contribute to the upper lip and primary palate. C) Decreased retinoic acid signaling results in decreased Lhx8 and Msx2 function. This in turn results in decreased growth and differentiation of the prominences that contribute to the upper lip and primary palate contributing to the formation of a median cleft. Abbreviations: mx; maxillary prominence, mnp; medial nasal prominence, ma; mandibular prominence, op; olfactory placode or pit.
